2016 Mobile Ad Summit
Date TBD
SIGN ME UP
Text goes here
X

Full Name

Company & Title

Description of person representing this event or brand. 

Full Name

Company & Title

Description of person representing this event or brand. 

Full Name

Company & Title

Description of person representing this event or brand. 

Date & Time TBD

Title

RSVP
Text goes here
X

Full Name

Company & Title

Description of person representing this event or brand. 

12pm - 1pm

How to Build Schedule Blocks

C. Doe

Mrs Robinson
Wishes you a wonderful day

Title

RSVP
Text goes here
X

Title

RSVP
Text goes here
X

About The Event

Clear your calendar - It's going down! Quote Blocks kicks off on April 26th, and you're invited to take part in the festivities. Join us for a day of fun and excitement. Come one, come all, bring a guest, and hang loose. This is going to be epic!

 INVOKANA® Simulcast Panel Program Registration

Early and Sustained Glycemic and

Cardiovascular Benefits With INVOKANA® 

Scroll Down to Register
Text goes here
X

Early and Sustained Glycemic and

Cardiovascular Benefits With INVOKANA® 

Scroll Down to Register

Scroll Down to Register
Text goes here
X

IMPORTANT SAFETY INFORMATION


 

INDICATIONS


INVOKANA® (canagliflozin) is indicated:


• as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD)
• to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria >300 mg/day


INVOKANA® is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

 

IMPORTANT SAFETY INFORMATION


   IMPORTANT SAFETY INFORMATION


WARNING: LOWER-LIMB AMPUTATION

•    An increased risk of lower-limb amputations associated with INVOKANA® use versus placebo was observed in CANVAS (5.9 vs 2.8 events per 1000 patient- years) and CANVAS-R (7.5 vs 4.2 events per 1000 patient-years), two large, randomized, placebo-controlled trials in patients with type 2 diabetes who had established cardiovascular disease (CVD) or were at risk for CVD.

•    Amputations of the toe and midfoot were most frequent; however, amputations involving the leg were also observed. Some patients had multiple amputations, some involving both limbs.

•    Before initiating, consider factors that may increase the risk of amputation, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers.
•    Monitor patients receiving INVOKANA® for infection, new pain or tenderness, sores, or ulcers involving the lower limbs, and discontinue if these complications occur.

CONTRAINDICATIONS     

CONTRAINDICATIONS     

•  Serious hypersensitivity reaction to INVOKANA®      

•  Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) who are being treated for glycemic control

•  Patients on dialysis

WARNINGS and PRECAUTIONS

• Lower-Limb Amputation: An increased risk of lower-limb amputations associated with INVOKANA® use versus placebo was observed in CANVAS (5.9 vs 2.8 events per 1000 patient-years) and CANVAS-R (7.5 vs 4.2 events per 1000 patient-years), two randomized, placebo-controlled trials evaluating patients with type 2 diabetes who had either established cardiovascular disease or were at risk for cardiovascular disease. The risk of lower-limb amputations was observed at both the 100-mg and 300-mg once-daily dosage regimens.  


Amputations of the toe and midfoot (99 out of 140 patients with amputations receiving INVOKANA® in the two trials) were the most frequent; however, amputations involving the leg, below and above the knee, were also observed (41 out of 140 patients with amputations receiving INVOKANA® in the two trials). Some patients had multiple amputations, some involving both lower limbs.


Lower-limb infections, gangrene, and diabetic foot ulcers were the most common precipitating medical events leading to the need for an amputation. The risk of amputation was highest in patients with a baseline history of prior amputation, peripheral vascular disease, and neuropathy.

             
Before initiating, consider factors in the patient history that may predispose to the need for amputations, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Counsel patients about the importance of routine preventative foot care. Monitor patients for signs and symptoms of infection (including osteomyelitis), new pain or tenderness, sores, or ulcers involving the lower limbs, and discontinue if these complications occur.


• Hypotension: INVOKANA® causes intravascular volume contraction. Symptomatic hypotension can occur after initiating INVOKANA®, particularly in the elderly, and in patients with impaired renal function, low systolic blood pressure, or on diuretics or medications that interfere with the renin-angiotensin-aldosterone system. Before initiating INVOKANA®, volume status should be assessed and corrected. Monitor for signs and symptoms after initiating.


• Ketoacidosis: Ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and 2 diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA®. Fatal cases of ketoacidosis have been reported in patients taking INVOKANA®. Before initiating INVOKANA®, consider factors in patient history that may predispose to ketoacidosis. For patients who undergo scheduled surgery, consider temporarily discontinuing INVOKANA® for at least 3 days prior to surgery. Monitor for ketoacidosis and temporarily discontinue in other clinical situations known to predispose to ketoacidosis. Ensure risk factors for ketoacidosis are resolved prior to restarting therapy. Educate patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue INVOKANA® and seek medical attention immediately if signs and symptoms occur.


• Acute Kidney Injury: INVOKANA® causes intravascular volume contraction and can cause acute kidney injury. Acute kidney injury, requiring hospitalization and dialysis, has been reported. Initiation of INVOKANA® may increase serum creatinine and decrease eGFR. Before initiation, consider factors that may predispose patients to acute kidney injury. Consider temporarily discontinuing INVOKANA® in any setting of reduced oral intake or fluid losses; monitor patients for signs and symptoms of acute kidney injury. If it occurs, promptly discontinue and treat. Evaluate renal function prior to initiation and monitor periodically thereafter. 


• Urosepsis and Pyelonephritis: Serious urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization have been reported in patients receiving SGLT2 inhibitors, including INVOKANA®. Treatment with SGLT2 inhibitors increases this risk. Evaluate for signs and symptoms and treat promptly.

 
• Hypoglycemia With Concomitant Use With Insulin and Insulin Secretagogues: INVOKANA® can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. A lower dose of insulin or insulin secretagogue may be required.

 

• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Necrotizing fasciitis of the perineum, a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, has been identified in postmarketing surveillance in female and male patients with diabetes mellitus receiving SGLT2 inhibitors, including INVOKANA®. Serious outcomes have included hospitalization, multiple surgeries, and death. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue INVOKANA®.  


• Genital Mycotic Infections: INVOKANA® increases risk of genital mycotic infections, especially in uncircumcised males or patients with prior infections. Monitor and treat appropriately.


• Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and anaphylaxis, were reported with INVOKANA®; these reactions generally occurred within hours to days after initiation. If reactions occur, discontinue INVOKANA®, treat, and monitor until signs and symptoms resolve.


• Bone Fracture: Increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in patients using INVOKANA®. Prior to initiation, consider factors that contribute to fracture risk.


DRUG INTERACTIONS


• UGT Enzyme Inducers: Co-administration with rifampin lowered INVOKANA® exposure, which may reduce the efficacy of INVOKANA®. For patients with eGFR ≥60 mL/min/1.73 m2, if an inducer of UGTs (eg, rifampin, phenytoin, phenobarbital, ritonavir) is co‑administered with INVOKANA®, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA® 100 mg. The dose may be increased to 300 mg once daily in patients currently tolerating INVOKANA® 200 mg and who require additional glycemic control.

For patients with eGFR <60 mL/min/1.73 m2, if an inducer of UGTs is co‑administered with INVOKANA®, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA® 100 mg. Consider adding another antihyperglycemic agent in patients who require additional glycemic control.


• Digoxin: There was an increase in the AUC and mean peak drug concentration of digoxin when co-administered with INVOKANA® 300 mg. Monitor appropriately.


• Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.


• Interference With 1,5-Anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.


USE IN SPECIFIC POPULATIONS  


• Pregnancy: INVOKANA® is not recommended in pregnant women, especially during the second and third trimesters.


• Lactation: INVOKANA® is not recommended while breastfeeding.


• Pediatric Use: Safety and effectiveness in patients <18 years of age have not been established.


• Geriatric Use: Patients ≥65 years had a higher incidence of adverse reactions related to reduced intravascular volume, particularly with the 300-mg dose; more prominent increase in the incidence was seen in patients who were ≥75 years. Smaller reductions in HbA1c relative to placebo were seen in patients ≥65 years.


• Renal Impairment: The efficacy and safety of INVOKANA® for glycemic control were evaluated in a trial that included patients with moderate renal impairment (eGFR 30 to <50 mL/min/1.73 m2). These patients had less overall glycemic efficacy, and patients treated with 300 mg per day had increases in serum potassium, which were transient and similar by the end of the study. Patients with renal impairment using INVOKANA® for glycemic control may be more likely to experience hypotension and may be at a higher risk for acute kidney injury. INVOKANA® is contraindicated in patients with ESKD on dialysis.


• Hepatic Impairment: INVOKANA® has not been studied in patients with severe hepatic impairment and is not recommended in this population.


OVERDOSAGE


• In the event of an overdose, contact the Poison Control Center and employ the usual supportive measures.


ADVERSE REACTIONS

•The most common adverse reactions associated with INVOKANA® (5% or greater incidence) were female genital mycotic infections, urinary tract infections, and increased urination.  

cp-68813v4

 
Please read accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide.

 

Should you have questions about the program, please contact Ileana Lavie at ilavie@decileten.com.

 

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

 

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

  

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

 

This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company, and are required to present information in compliance with FDA requirements for communications about its medicines.

 

The personal information you provide may be used to contact you about your request to attend the Janssen Pharmaceuticals, Inc., program using your preferred method of communication as indicated by you. This information may be shared with Janssen Pharmaceuticals, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.    


CONTRAINDICATIONS     

• Serious hypersensitivity reaction to INVOKANA®      

• Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis

Program Details


Please join us for an engaging multidisciplinary panel discussion. Several opportunities are available to view this presentation via the Web. See below for the available dates and click on your preferred date to see further details on the times offered as well as the faculty presenters.


Program Overview 


 

A multidisciplinary panel will discuss the management of diabetic kidney disease in adults with type 2 diabetes. 

 The discussion will include:

 •  The burden of diabetic kidney disease, including prevalence and outcomes 

 •  Clinical trial results in patients with diabetic kidney disease and type 2 diabetes
 •  Important Safety Information

 •  Live question-and-answer session


Click Here for More Information and to Register for March 31, 2020
Text goes here
X


• Pregnancy: INVOKANA® is not recommended in pregnant women, especially during the second and third trimesters.


• Nursing Mothers: INVOKANA® is not recommended while breastfeeding.


• Pediatric Use: Safety and effectiveness in patients <18 years of age have not been established.


• Geriatric Use: Patients ≥65 years had a higher incidence of adverse reactions related to reduced intravascular volume, particularly with the 300-mg dose; more prominent increase in the incidence was seen in patients who were ≥75 years. Smaller reductions in HbA1c relative to placebo were seen in patients ≥65 years.


• Renal Impairment: Patients with moderate renal impairment (eGFR 30 to <50 mL/min/1.73 m2) had less overall glycemic efficacy and a higher occurrence of adverse reactions related to reduced intravascular volume, renal-related adverse reactions, and decreases in eGFR compared to patients with mild renal impairment or normal renal function (eGFR ≥60 mL/min/1.73 m2); patients treated with 300 mg were more likely to experience increases in potassium. INVOKANA® is not recommended in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), with end-stage renal disease, or receiving dialysis.


• Hepatic Impairment: INVOKANA® has not been studied in patients with severe hepatic impairment and is not recommended in this population.


OVERDOSAGE

• In the event of an overdose, contact the Poison Control Center and employ the usual supportive measures.



 • The most common adverse reactions associated with INVOKANA® (5% or greater incidence) were female genital mycotic infections, urinary tract infections, and increased urination.  


  cp-68813v2

 
Please see accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide.

 

Should you have questions about the program, please contact <Ileana Lavie> at <ilavie@decileten.com>.

 

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

 

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

  

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

 

This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company, and are required to present information in compliance with FDA requirements for communications about its medicines.

 

The personal information you provide may be used to contact you about your request to attend the Janssen Pharmaceuticals, Inc. program using your preferred method of communication as indicated by you. This information may be shared with Janssen Pharmaceuticals, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.    

Text Block #8

Program Information


Program Overview

Starting your own business and picking the right niche in no time


IMPORTANT SAFETY INFORMATION

WARNING: LOWER-LIMB AMPUTATION

      • An approximately 2-fold increased risk of lower-limb amputations associated with INVOKANA® use was observed in CANVAS and CANVAS-R, two large, randomized,

        placebo-controlled trials in patients with type 2 diabetes who had established cardiovascular disease (CVD) or were at risk for CVD. 

      • Amputations of the toe and midfoot were most frequent; however, amputations involving the leg were also observed. Some patients had multiple amputations, some involving 

        both limbs.

      • Before initiating, consider factors that may increase the risk of amputation, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers.

      • Monitor patients receiving INVOKANA® for infection, new pain or tenderness, sores, or ulcers involving the lower limbs, and discontinue if these complications occur. 

CONTRAINDICATIONS    
       • History of a serious hypersensitivity reaction to INVOKANA®, such as anaphylaxis or angioedema       

       • Severe renal impairment (eGFR <30 mL/min/1.73 m2 ), end-stage renal disease, or patients on dialysis

 WARNINGS and PRECAUTIONS

       • Lower-Limb Amputation: An approximately 2-fold increased risk of lower-limb amputations associated with INVOKANA® use was observed in CANVAS and CANVAS-R, two large,

         randomized, placebo-controlled trials evaluating patients with type 2 diabetes who had either established cardiovascular disease or were at risk for cardiovascular disease. In

         CANVAS, INVOKANA®-treated patients and placebo-treated patients had 5.9 and 2.8 amputations per 1000 patients per year, respectively. In CANVAS-R, INVOKANA®-treated patients

         and placebo-treated patients had 7.5 and 4.2 amputations per 1000 patients per year, respectively. The risk of lower-limb amputations was observed at both the 100-mg and 300-mg

         once-daily dosage regimens.


          Amputations of the toe and midfoot (99 out of 140 patients with amputations receiving INVOKANA® in the two trials) were the most frequent; however, amputations involving the leg,

          below and above the knee, were also observed (41 out of 140 patients with amputations receiving INVOKANA® in the two trials). Some patients had multiple amputations, some

          involving both lower limbs.


          Lower-limb infections, gangrene, and diabetic foot ulcers were the most common precipitating medical events leading to the need for an amputation. The risk of amputation was

          highest in patients with a baseline history of prior amputation, peripheral vascular disease, and neuropathy.


          Before initiating, consider factors in the patient history that may predispose to the need for amputations, such as a history of prior amputation, peripheral vascular disease,

          neuropathy, and diabetic foot ulcers. Counsel patients about the importance of routine preventative foot care. Monitor patients for signs and symptoms of infection (including

          osteomyelitis), new pain or tenderness, sores, or ulcers involving the lower limbs, and discontinue if these complications occur.

      •  Hypotension: INVOKANA® causes intravascular volume contraction. Symptomatic hypotension can occur after initiating INVOKANA®, particularly in patients with impaired renal

          function (eGFR <60 mL/min/1.73 m2), elderly patients, patients on either diuretics or medications that interfere with the renin‐angiotensin‐aldosterone system, or patients with low

          systolic blood pressure. Before initiating in patients with ≥1 of these characteristics, volume status should be assessed and corrected. Monitor for signs and symptoms after

          initiating. 

      •  Ketoacidosis: Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, have been identified in patients with type 1 and 2 diabetes mellitus receiving SGLT2

           inhibitors, including INVOKANA®. Fatal cases of ketoacidosis have been reported in patients taking INVOKANA®.  Before initiating INVOKANA®, consider factors in patient history that may

           predispose to ketoacidosis, including pancreatic insulin deficiency, caloric restriction disorders, and alcohol abuse. In patients treated with INVOKANA®, consider monitoring for ketoacidosis

           and temporarily discontinuing in clinical situations known to predispose to ketoacidosis (eg, prolonged fasting due to acute illness or surgery).

      •  Acute Kidney Injury and Impairment in Renal Function: INVOKANA® causes intravascular volume contraction and can cause renal impairment. Postmarketing reports of acute kidney injury, some

           requiring hospitalization and dialysis, were reported; some reports involved patients younger than 65 years of age. Before initiation, consider factors that may predispose patients to acute kidney

           injury including hypovolemia, chronic renal insufficiency, congestive heart failure and concomitant medications. Consider temporarily discontinuing INVOKANA® in any setting of reduced oral

           intake or fluid losses; monitor patients for signs and symptoms of acute kidney injury. If acute kidney injury occurs, discontinue promptly and institute treatment.


           INVOKANA® increases serum creatinine and decreases eGFR. Patients with hypovolemia may be more susceptible to these changes. Renal function abnormalities can occur after initiation. Renal

           function should be evaluated prior to initiation and periodically thereafter. Dose adjustment and more frequent renal function monitoring are recommended in patients with an

           eGFR <60 mL/min/1.73 m2.

      • Hyperkalemia: INVOKANA® can lead to hyperkalemia. Patients with moderate renal impairment who are taking medications that interfere with potassium excretion or medications that interfere

          with the renin‐angiotensin‐aldosterone system are more likely to develop hyperkalemia. Monitor serum potassium levels periodically in patients with impaired renal function and in patients

          predisposed to hyperkalemia due to medications or other medical conditions.

      • Urosepsis and Pyelonephritis: There have been reports of serious urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization in patients receiving SGLT2 inhibitors,

          including INVOKANA®. Treatment with SGLT2 inhibitors increases this risk. Evaluate patients for signs and symptoms and treat promptly.

      • Hypoglycemia With Concomitant Use With Insulin and Insulin Secretagogues: INVOKANA® can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. A lower

          dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with INVOKANA®.
      • Genital Mycotic Infections: INVOKANA® increases risk of genital mycotic infections. Patients with history of these infections and uncircumcised males were more likely to develop these infections.

          Monitor and treat appropriately.        

      • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and anaphylaxis, were reported with INVOKANA®; these reactions generally occurred within hours to days after

          initiation. If reactions occur, discontinue INVOKANA®, treat per standard of care, and monitor until signs and symptoms resolve.

      • Bone Fracture: Increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in patients using INVOKANA®.  Consider factors that contribute to fracture

          risk prior to initiating INVOKANA®. 

      • Increases in Low‐Density Lipoprotein (LDL‐C): Dose‐related increases in LDL‐C can occur with INVOKANA®. Monitor LDL-C and treat per standard of care after initiating.

      • Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with INVOKANA®.

 

 DRUG INTERACTIONS
    • UGT Enzyme Inducers: Rifampin: Co-administration of INVOKANA® with rifampin decreased INVOKANA® area under the curve (AUC) by 51% and therefore may decrease efficacy. If an inducer of

        UGT enzymes must be co-administered with INVOKANA®, consider increasing the dose to 300 mg once daily if patients are currently tolerating INVOKANA® 100 mg once daily, have an

        eGFR ≥60 mL/min/1.73 m2, and require additional glycemic control. Consider other antihyperglycemic therapy in patients with an eGFR <60 mL/min/1.73 m2  who require additional glycemic    

        control.

    • Digoxin: There was an increase in the AUC and mean peak drug concentration of digoxin (20% and 36%, respectively) when co‐administered with INVOKANA® 300 mg. Monitor appropriately.

    • Positive Urine Glucose Test: Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and

        will lead to positive urine glucose test results. Use alternative methods to monitor glycemic control.

    • Interference With 1,5-Anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control

        in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

       

 USE IN SPECIFIC POPULATIONS

     • Pregnancy: Based on animal data showing adverse renal effects, INVOKANA® is not recommended during the second and third trimesters of pregnancy. Limited data with INVOKANA® in

         pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to mother and fetus associated with poorly controlled diabetes in

         pregnancy.

     • Nursing Mothers: There is no information regarding the presence of INVOKANA® in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for

         serious adverse reactions in a breastfed infant, advise women that use of INVOKANA® is not recommended while breastfeeding.

     • Pediatric Use: Safety and effectiveness in patients <18 years of age have not been established.

     • Geriatric Use: 2034 patients ≥65 years and 345 patients ≥75 years were exposed to INVOKANA® in 9 clinical studies. Patients ≥65 years had a higher incidence of adverse reactions related to

         reduced intravascular volume (eg, hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration), particularly with the 300‐mg dose, compared to younger patients; more

         prominent increase in the incidence was seen in patients who were ≥75 years. Smaller reductions in HbA1c relative to placebo were seen in patients ≥65 years (‒0.61% with INVOKANA® 100 mg

         and ‒0.74% with INVOKANA® 300 mg) compared to younger patients (‒0.72% with INVOKANA® 100 mg and ‒0.87% with INVOKANA® 300 mg).

     • Renal Impairment: Efficacy and safety were evaluated in a study that included patients with moderate renal impairment (eGFR 30 to <50 mL/min/1.73 m2). These patients had less overall glycemic

         efficacy and a higher occurrence of adverse reactions related to reduced intravascular volume, renal‐related adverse reactions, and decreases in eGFR compared to patients with mild renal

         impairment or normal renal function (eGFR ≥60 mL/min/1.73 m2); patients treated with 300 mg were more likely to experience increases in potassium. INVOKANA® is not recommended in

         patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), with end‐stage renal disease, or receiving dialysis.

     • Hepatic Impairment: INVOKANA® has not been studied in patients with severe hepatic impairment and is not recommended in this population.


 OVERDOSAGE
     • In the event of an overdose, contact the Poison Control Center and employ the usual supportive measures, eg, remove unabsorbed material from the gastrointestinal tract, employ clinical

         monitoring, and institute supportive treatment as needed.

 

 ADVERSE REACTIONS

     • The most common adverse reactions associated with INVOKANA® (5% or greater incidence) were female genital mycotic infections, urinary tract infections, and increased urination.

 

 076189-170713


Please see accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide.

 

Should you have questions about the program, please contact Aimee Bauer (abauer@decileten.com). 

 

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

 

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal or other items of value you receive may be publicly disclosed. If you are licensed  in any state or other  jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

  

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation. This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company, and are required to present information in compliance with FDA requirements for communications about its medicines.

 

The personal information you provide may be used to contact you about your request to attend the Janssen Pharmaceuticals, Inc., program using your preferred method of communication as indicated by you.  This information may be shared with Janssen Pharmaceuticals, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.    


 The information you provide will be used by Janssen Pharmaceuticals, Inc., our affiliates, and our service providers for the registration, fulfillment, and administration of the KOL Panel Simulcast program, and to  fulfill other requests you may select. Our Privacy Policy governs the use of information you provide.         

   


Program Details

I understand by providing my information, I am registering for this program, for which the information will be used to manage my participation.


The information will be used by Janssen Pharmaceuticals, Inc., our affiliates, and our service providers involved in the KOL Panel Simulcast Program. Our Privacy Policy governs the use of information you provide.

Click Here to Register
Text goes here
X
Faculty Presenters
Text goes here
X
Program Overview
Text goes here
X

Mrs Robinson
Wishes you a wonderful day

Text Block #1

Starting your own business and picking the right niche in no time


Faculty Presenters

Speakers for [Month Day] Program

Nassir Azimi, MD, FACC, FSCAI, FASNC

Cardiology

La Mesa Cardiac Center

La Mesa, CA

Bruce Bode, MD


Internal Medicine

Atlanta Diabetes Associates

Atlanta, GA

Sagar Panse, MD, MS


Nephrology

Central Georgia Kidney Specialists

Macon, GA

Steve Vacalis, DO


Primary Care

CaroMont Family Medicine

Charlotte, NC

Speakers for October 26 Program

Javed Butler, MD, MPH, MBA


Cardiology

Stony Brook University

Stony Brook, NY

James Gavin III, MD, PhD


Endocrinology

Emory University School of Medicine

Atlanta, GA

Sagar Panse, MD, MS


Nephrology

Central Georgia Kidney Specialists

Macon, GA

John Sink, PA-C, CDE

 

Physician Assistant

Jones Center for Diabetes

Macon, GA

Speakers for November 2 Program

John Anderson, MD


Internal Medicine


The Frist Clinic

Nashville, TN

Javed Butler, MD, MPH, MBA


Cardiology


Stony Brook University 

Stony Brook, NY

Serge Jabbour, MD


Endocrinology

Sidney Kimmel Medical College at Thomas Jefferson University

Philadelphia, PA

Christian Mende, MD, FACP, FACN, FASN, FASH

Nephrology


University of California, San Diego 

La Jolla, CA

Speakers for November 7 Program

Matt Budoff, MD, FACC, FAHA


Cardiology

University of California, Los Angeles

Torrance, CA

Yehuda Handelsman, MD, FLNA, FACP, MACE

Endocrinology

Metabolic Institute of America

Tarzana, CA

Pam Kushner, MD, MA


Primary Care

Private Practice

Irvine, CA

Sagar Panse, MD, MS


Nephrology

Central Georgia Kidney Specialists

Macon, GA

Program Overview

A multidisciplinary panel will discuss the long-term results with INVOKANA® across a broad range of patients with type 2 diabetes. The discussion will include:

      •   Long-term safety and efficacy results with INVOKANA® in patients with type 2 diabetes followed for up for 6.5 years

      •   Clinical results demonstrating superior reductions in A1C (300-mg dose*), body weight, and systolic blood pressure† with similar overall tolerability with INVOKANA® versus Januvia®                and glimepiride
      •   A1C and safety results from a network meta-analysis of INVOKANA®, Jardiance®, and Farxiga® 
      •   Important Safety Information

      •   Live question-and-answer session

   

†The recommended starting dose for INVOKANA® is 100 mg once daily. 

*INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.

A multidisciplinary panel will discuss the long-term results with INVOKANA® across a broad range of patients with type 2 diabetes. The discussion will include:

      •   Long-term safety and efficacy results with INVOKANA® in patients with type 2 diabetes followed for up for 6.5 years

      •   Clinical results demonstrating superior reductions in A1C (300-mg dose*), body weight, and systolic blood pressure† with similar overall tolerability with INVOKANA® versus Januvia®                and glimepiride
      •   A1C and safety results from a network meta-analysis of INVOKANA®, Jardiance®, and Farxiga® 
      •   Important Safety Information

      •   Live question-and-answer session

   

†The recommended starting dose for INVOKANA® is 100 mg once daily. 

*INVOKANA® is not indicated for weight loss or as an antihypertensive treatment.

[Day, Date]

 

[Time] (Eastern)
[Time] (Eastern)

[Time] (Eastern)

Register above

[Day, Date]

[Time] (Eastern)

[Time] (Eastern)

[Time] (Eastern)

Register above

[Day, Date]

[Time] (Eastern)
[Time] (Eastern)

[Time] (Eastern)

Register above

 

Please join us for an engaging multidisciplinary panel discussion of the long-term results with INVOKANA® across a broad range of patients with type 2 diabetes.

Several opportunities are available to view this presentation via the Web.


See below for the available dates and click on your preferred date to see further details on the times offered, the faculty presenters and to register.

Program Details

Please join us for an engaging multidisciplinary panel discussion on INVOKANA® in patients with type 2 diabetes. Several opportunities are available to view this presentation via the Web. See below for the available dates and click on your preferred date to see further details on the times offered as well as the faculty presenters.

For more information on the times available and the faculty for each program, please click the button below for the date you would like to view the program.

© Janssen Pharmaceuticals, Inc. 2020          February 2020          cp-106094v2



Search
[confirmation_headline]
[confirmation_messaging]
Add to Calendar
Text goes here
X
Powered by Splash
CONTACT THE ORGANIZER
Google   Outlook   iCal   Yahoo

Sign Me Up

Which session would you like to attend?
Please tell us if you are a Healthcare Professional or a Sales Representative
If you are a Healthcare Professional, please provide your degree
Please provide your specialty
processing image...
Add to my Calendar
  • Google  Outlook  iCal  Yahoo